NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +71.15%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.49, delivering a surprise of -8.89%.Over the last four quarters, the ...